These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19909906)

  • 1. Do interferon beta-1b and glatiramer acetate grow brain?
    Rudick RA; Fisher E
    Lancet Neurol; 2009 Dec; 8(12):1085-6; author reply 1086-7. PubMed ID: 19909906
    [No Abstract]   [Full Text] [Related]  

  • 2. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
    O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
    Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
    Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
    Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate for multiple sclerosis.
    Drug Ther Bull; 2001 Jun; 39(6):41-3. PubMed ID: 11432030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
    Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
    J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate.
    Yildiz M; Tettenborn B; Putzki N
    Eur Neurol; 2011; 65(4):231-2. PubMed ID: 21454981
    [No Abstract]   [Full Text] [Related]  

  • 9. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
    Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of inflammation on brain volume in multiple sclerosis.
    Cheriyan J; Kim S; Wolansky LJ; Cook SD; Cadavid D
    Arch Neurol; 2012 Jan; 69(1):82-8. PubMed ID: 22232347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.
    Gartzen K; Limmroth V; Putzki N
    Eur J Neurol; 2007 Jun; 14(6):e12-3. PubMed ID: 17539924
    [No Abstract]   [Full Text] [Related]  

  • 15. Glatiramer: new preparation. No place in multiple sclerosis.
    Prescrire Int; 2004 Feb; 13(69):10-2. PubMed ID: 15055208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
    Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
    Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hass J, Firzlaff M (2005). Twenty-four-month comparison of immunomodulatory treatments--a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). European Journal of Neurology 12:425-431.
    Hasford J
    Eur J Neurol; 2005 Nov; 12(11):916-7; author reply 917. PubMed ID: 16241986
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
    Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP
    Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.